Скачать или смотреть Inside the Data Driving Hope in Pancreatic Cancer | $ACTU | Actuate Therapeutics

In this edition of The Upside, Lou Basenese sits down with Dan Schmitt, CEO of Actuate Therapeutics, the biotech behind a potential breakthrough in one of the deadliest cancers. Actuate’s lead drug, elraglusib, doubled one-year survival when added to standard chemo. After treating more than 500 patients, the data points to a true “pipeline in a molecule” with applications far beyond pancreatic cancer. Schmitt explains why upcoming regulatory milestones could be transformative – and why the market still hasn’t priced in the company’s multi-billion-dollar opportunity.

📈 Could this become the next backbone therapy in oncology?

💡 Watch to learn why analysts are calling it a “pipeline in a molecule.”

💡 Learn more: https://tbsupside.com/actu

Not financial advice. For entertainment only. See full Terms & Conditions on TBSUpside.com

- - - - - - - - - - - - - - - - - -

👉 Follow Lou on Social Media:
Twitter: https://x.com/LouBasenese
LinkedIn:   / lou-basenese-174821128  

- - - - - - - - - - - - - - - - - -
⏰ CHAPTERS:
- - - - - - - - - - - - - - - - - -
00:00 — Why pancreatic cancer needs a breakthrough
01:04 — Why Big Pharma failed to drug GSK-3
02:08 — Elraglusib: what makes it different
03:41 — Dan Schmitt’s background and acquisition track record
05:31 — Today’s standard of care in pancreatic cancer
08:21 — Phase 2 results: doubling one-year survival
10:55 — Quality of life and safety profile
13:06 — Market size: a $5B pancreatic cancer opportunity
14:48 — Pipeline beyond pancreatic cancer
16:53 — How the drug boosts the immune response
18:41 — Patent protection through 2043
19:51 — Competitive landscape and combo-therapy potential
21:29 — Risk, valuation, and why the market missed this
23:44 — Final takeaway: extending human life is the real upside

$ACTCU #BiotechStocks #CancerAwareness #InvestingInBiotech #LifeSciences #CancerTreatment #FutureOfMedicine #MedicalInnovation #BreakthroughScience #ExtendLife #NewDrugDevelopment